TIDMAVCT
RNS Number : 2088V
Avacta Group PLC
13 April 2021
13 April 2021
Avacta Group plc
("Avacta" or "the Group")
Notice of Results and Investor Presentation
Avacta Group plc (AIM: AVCT), the developer of diagnostics and
innovative cancer therapies based on its proprietary Affimer(R) and
pre|CISION(TM) platforms, will announce its financial results for
the 12 months ended 31 December 2020 on Thursday, 22 April
2021.
Analyst briefing
A sell-side analyst briefing given by Alastair Smith, Chief
Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil
Bell, Chief Development Officer, will be held by webcast
presentation, followed by a Q&A session, at 9.30am BST on
Thursday, 22 April 2021.
Pre-registration is required for attendance to the call. To
confirm attendance, please email
Avacta@fticonsulting.com and you will be sent the link to join.
The presentation will be posted on the Company's website at the
following address:
https://avacta.com/investors/documents-presentations
Investor webinar
An investor webinar presentation by Alastair Smith, Chief
Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil
Bell, Chief Development Officer, will take place at 11:00am BST on
Thursday, 22 April 2021.
The webinar is open to all existing and potential investors and
will consist of a presentation followed by a Q&A session, held
on the Investor Meet Company platform. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free and then
click "Add to meet" Avacta Group via the following link to join the
webinar:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta Group plc on the Investor
Meet Company platform will automatically be invited.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive Officer www.avacta.com
Tony Gardiner, Chief Financial Officer
finnCap Ltd (Nominated Adviser and Joint Broker) Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Corporate Finance www.finncap.com
Tim Redfern - ECM
Stifel Nicolaus Europe Limited (Joint Broker) Tel: +44 (0) 207 710 7600
Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison www.stifel.com
FTI Consulting (Financial Media and IR) Tel: +44 (0) 203 727 1000
Simon Conway / Stephanie Cuthbert Avacta.LS@fticonsulting.com
Zyme Communications (Trade and Regional Media) Tel: +44 (0) 7787 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing diagnostics and innovative cancer
therapies based on its proprietary platforms - Affimer(R) biologics
and pre|CISION(TM) tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived
from a small human protein. Despite their shortcomings, antibodies
currently dominate markets, such as diagnostics and therapeutics,
worth in excess of $100bn. Affimer technology has been designed to
address many of these negative performance issues, principally: the
time taken to generate new antibodies and the reliance on an
animal's immune response; poor specificity in many cases; their
large size, complexity and high cost of manufacture.
Avacta's pre|CISION(TM) targeted chemotherapy platform releases
active chemotherapy in the tumour, which limits the systemic
exposure that causes damage to healthy tissues, and thereby
improves the overall safety and therapeutic potential of these
powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development
activities are based in Cambridge, UK and the Group is generating
near-term revenues from Affimer reagents for diagnostics,
bioprocessing and research, through a separate diagnostics business
unit based in Wetherby, UK.
Avacta's Diagnostics Division works with partners world-wide to
develop bespoke Affimer reagents for third party products. The
Group is also developing an in-house pipeline of Affimer-based
diagnostic assays including the AffiDX (R) SARS-CoV-2 Lateral Flow
Rapid Antigen Test and an AffiDX (R) BAMS(TM) SARS-CoV-2 Assay in
partnership with Adeptrix Inc.
Avacta's Therapeutics Division is addressing a critical gap in
current cancer treatment - the lack of a durable response to
current immunotherapies experienced by most patients. By combining
its two proprietary platforms the Group is building a wholly owned
pipeline of novel cancer therapies deigned to be effective for all
cancer patients. In 2021 Avacta will commence a phase 1
first-in-human, open label, dose-escalation and expansion study of
AVA6000 Pro-doxorubicin, the Group's lead pre|CISION(TM) prodrug,
in patients with locally advanced or metastatic selected solid
tumours.
Avacta has established drug development partnerships with pharma
and biotech, including a research collaboration with ModernaTX,Inc.
(formerly Moderna Therapeutics Inc.), a multi-target deal with LG
Chem worth up to $400m, a joint venture in South Korea with
Daewoong Pharmaceutical focused on cell and gene therapies
incorporating Affimer immune-modulators, a partnership with ADC
Therapeutics to develop Affimer-drug conjugates and a collaboration
with Point Biopharma to develop radiopharmaceuticals based on the
pre|CISION(TM) platform. Avacta continues to actively seek to
license its proprietary platforms in a range of therapeutic
areas.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAKLAFLNFEFA
(END) Dow Jones Newswires
April 13, 2021 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
